Xilio Therapeutics (XLO) Fundamental Analysis: Revenue, Earnings & Valuation

6.62 / 10

Outperform

Fundamental analysis rates the stock Outperform with a 6.6/10 score. Strong points include Asset‑MV, Profit‑MV, Cash‑MV and inventory turnover. Weaknesses appear in current and fixed assets turnover and revenue‑MV. Overall outlook is encouraging but not flawless.

Analysis Checks(6/10)

Revenue-MV

Value0.64

Score1/3

Weight8.90%

1M Return5.44%

Inventory turnover ratio

Value47.57

Score3/3

Weight10.80%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight2.29%

1M Return1.67%

Profit-MV

Value0.41

Score2/3

Weight10.16%

1M Return6.36%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.25%

1M Return0.21%

Current assets turnover ratio

Value0.33

Score0/3

Weight-1.90%

1M Return-1.61%

Fixed assets turnover ratio

Value3.57

Score1/3

Weight-1.32%

1M Return-1.13%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight5.37%

1M Return4.08%

Asset-MV

Value-0.48

Score3/3

Weight30.41%

1M Return15.70%

Cash-MV

Value-0.09

Score3/3

Weight35.03%

1M Return15.07%

Is XLO undervalued or overvalued?

XLO scores 6.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its -132.53% ROE, -80.05% net margin, -1.41 P/E ratio, 1.40 P/B ratio, and 72.51% earnings growth, these metrics solidify its Outperform investment rating.